-
Press ReleaseNovartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
-
Press ReleaseNovartis announces plans to build flagship manufacturing hub in North Carolina
-
Press ReleaseNovartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
-
Press ReleaseNovartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht
-
Press ReleaseNovartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024
-
Press ReleaseNovartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
-
Press ReleaseNew Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
-
Press ReleaseNovartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
-
Press ReleaseNovartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III
-
Press ReleaseNovartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
-
Press ReleaseStarkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen
-
Press ReleaseNovartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors